The 26th James Bond feature will be helmed by director Denis Villeneuve from a script penned by Steven Knight, though the title and exact release window remain undisclosed. Robert Pattinson secured the landmark role after screen testing alongside contenders Josh O'Connor, Callum Turner, and Jack Lowden. Producers Amy Pascal and David Heyman selected Pattinson for his versatility and wit, while Villeneuve highlighted his ability to bring a fresh yet timeless energy to 007.
Key points
Robert Pattinson becomes the seventh actor to play the legendary secret agent on the big…: Robert Pattinson becomes the seventh actor to play the legendary secret agent on the big screen.
Longtime franchise stewards Barbara Broccoli and Michael G. Wilson have formally stepped…: Longtime franchise stewards Barbara Broccoli and Michael G. Wilson have formally stepped back from producing.
Several British actors including Josh O'Connor, Callum Turner, and Jack Lowden also teste…: Several British actors including Josh O'Connor, Callum Turner, and Jack Lowden also tested for the role.
Sources checked by our analysis pipeline: 1
- Published
Robert Pattinson, the British actor known for films such as Twilight and The Batman, has been confirmed as the next actor to play James Bond.
The announcement was made by Amazon MGM Studios in a social media post on Monday, with a picture showing Pattinson in character as 007.
The 40-year-old becomes the seventh actor to play the famous fictional spy and will star in the 26th Bond movie, due to be released in 2028.
In a statement, the London-born actor said: "James Bond is one of the most legendary characters in cinema, and to be entrusted with 007 is the honour of a lifetime."
The next Bond film will be directed by Denis Villeneuve and written by Steven Knight, but its title and exact release date have not yet been announced.
In his statement, Pattinson said he was "deeply gratreful" to the film's creative team "for their belief in me".
"To say this role is a dream come true is an understatement," he added. "I couldn't be more excited about this partnership and the work ahead with…
Investors aggressively backed the target company after an international pharmaceutical player launched a massive buyout proposal. The multi-million-dollar move marks a pivotal acquisition bid for the drug manufacturer. The proposal is poised to significantly reshape the firm's ownership structure.
Officials are preparing to enter formal discussions concerning the operational future of the commercial facility. The forthcoming dialogue aims to address the status of the shuttered site and evaluate conditions surrounding its activity. Stakeholders anticipate these preliminary engagements will clarify whether operations can legally and safely resume.
A company-wide web disruption compromised vital flight-planning tools, forcing carriers to ground departures while leaving airborne and regional partner flights unaffected. The internal software failure prevented pilots from receiving the mandatory weight calculations necessary for clearing takeoffs. As a result, hundreds of schedules were thrown off course, with some aircraft even forced to abandon their taxiing and return to gates.